US clears first ‘living drug’ for tough childhood leukemia – Carlisle Sentinel
The Pharma Letter (registration) |
US clears first 'living drug' for tough childhood leukemia
Carlisle Sentinel The CAR–T cell treatment developed by Novartis and the University of Pennsylvania is the first type of gene therapy to hit the U.S. market — and one in a powerful but expensive wave of custom-made "living drugs" being tested against blood cancers and … Today's miracle is tomorrow's also-ran in hottest cancer field Following IBMTR model may make CAR–T therapies affordable, says oncologist and data specialist Landmark Approval of Kymriah Won, Novartis' Next Test Is Scaling CAR–T Manufacturing |
